New inclisiran formula tested for high cholesterol safety
NCT ID NCT07626281
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether a new version of the cholesterol-lowering drug inclisiran, which includes an ingredient called polysorbate 80, is as safe and works as well as the current version. About 120 healthy adults with moderately high LDL cholesterol will receive a single injection of one of the two formulations. Researchers will compare how the drug moves through the body and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inclisiran (a cholesterol-lowering drug) with or without polysorbate 80
What this could lead to
If successful, this could lead to a new formulation of inclisiran that is just as safe and effective as the current one, potentially offering more options for managing high cholesterol.
What could go wrong
This is an early Phase 1 study with only 120 healthy volunteers, so results may not apply to all patients. The new formulation might not work as well or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCLISIRAN FORMULATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact